Second Line Chemotherapy for Advanced Pancreatic Cancer

Phase 2 Completed 50 enrolled Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente Hospira, now a wholly owned subsidiary of Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

No validated second-line chemotherapy for the treatment of locally advanced/metastatic pancreatic cancer is actually available,after the failure of a gemcitabine(+/- Cisplatin or Oxaliplatin)-based regimen. Irinotecan seems to be a moderately active drug in the treatment of this disease Recently was reported some interesting results using a potentially non -cross resistant regimen (FOLFIRI) which could be useful even as second-line chemotherapy. An exploratory study in this setting seem warranted.

Timeline

Start: 2010-01
Primary completion: 2011-06
Completion: 2011-12

Publications

Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, Valmadre G, Ferrara D, Veltri E, Codignola C, Labianca R. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol. 2012 Jun;69(6):1641-5. doi: 10.1007/s00280-012-1875-1. Epub 2012 May 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Irinotecan	Small molecule	180 mg/m2	Intravenous
Background	Leucovorin	Small molecule	200 mg/m2	Intravenous
Background	fluorouracil	Small molecule	400 mg/m2	Intravenous
Background	fluorouracil	Small molecule	600 mg/m2	Intravenous

Second Line Chemotherapy for Advanced Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications